China Infant Milk Formula: Recall Impact is Transient, Consolidation and Adult Nutrition Drive the Next Chapter

Core Conclusion

The recent global infant formula recalls will not cause a durable share shift between foreign and domestic brands; market share is expected to normalise by end-2026. The real investment themes are structural volume decline from falling birthrates (net volumes down 5-10% in 2026), industry consolidation, and the emerging adult nutrition segment. Companies with strong innovation, premium product positioning, and adult nutrition exposure—Yili, Danone, A2M, and Mengniu—are best positioned. Nestle faces headwinds from its Wyeth Nutrition brands.

Evidence Chain: Three Key Themes

Theme 1: Recall Aftermath – No Lasting Share Shift

The expert assesses that most foreign and domestic brands were affected by recent recalls, diluting the potential for any single group to gain meaningfully. Danone and Nestle have largely passed through the largest recall impacts, with underlying market share beginning to normalise. A2M's supply disruptions, stemming from new testing requirements and production issues, may have been misinterpreted by consumers as a recall event, creating a headwind. However, once supply normalises in June, A2M can rebuild positive consumer sentiment. The key swing factor for A2M is the speed of supply restoration, not a permanent loss of shelf space.
Investment implication: Near-term noise in A2M's share from supply constraints is temporary; the company's medium- to long-term share gain opportunity remains intact. For Danone and Nestle, the recall overhang is largely priced in, and normalisation supports current ratings.

Theme 2: Structural Volume Decline and Premiumisation

Birthrates are expected to fall again in 2026, based on mid-single-digit declines in marriage registrations and early provincial birth registration data showing 10-13% drops. This implies an overall market volume decline of 5-10%, with the low-end segments hit hardest. The mix shift is already evident: Stage 3 formula now accounts for 60-70% of infant formula sales. Low-single-digit pricing increases are possible if oil prices remain elevated, offering a partial offset.
Investment implication: Volume-driven growth is structurally challenged; only players who can drive premiumisation through innovation (e.g., specialty formulas, older-stage products) will sustain revenue. Yili and Danone are cited as well-placed for pricing and premium shift. The weakness in lower-tier brands (Feihe) aligns with this trend.

Theme 3: Consolidation and the Adult Nutrition Opportunity

The expert sees further consolidation opportunity in infant formula, with foreign brands still positioned to take share over the long term via innovation and exploiting domestic missteps. More importantly, adult nutrition (milk powder for adults, elderly) is a key opportunity with strong fundamentals. The kids' supplement market is immature but contested. Among domestic players, Yili and H&H are expected to gain IMF share, while Feihe loses. Among foreign, Danone stable-to-improving, Nestle losing (Wyeth drag), A2M gaining if supply recovers.
Investment implication: The adult nutrition tailwind is underappreciated. Danone and Yili are highlighted as having upside from adult formula. Mengniu, though a smaller IMF player, is recognised as meaningful in adult milk powder and posted high-double-digit milk powder growth in 1Q26.

Key Risks

• Deeper birthrate decline: If 2026 registrations fall more than the expected 10-13%, the volume hit could exceed 10%, pressuring margins across the board.
• Supply recovery delay for A2M: If testing capacity ramps slower than June, A2M's positive sentiment could erode further, risking market share loss that becomes durable.
• Renewed price competition: Low-single-digit pricing may not hold if domestic players retaliate to defend share in a shrinking market.
• Execution risk in adult nutrition: This segment requires different distribution and marketing; not all infant formula players will succeed.

Valuation and Trading Implications

The combination of recall normalisation and structural shifts favours companies with premium portfolios, adult nutrition exposure, and demonstrated execution. Current ratings reflect this:

• Overweight on A2M, Danone, Yili, Mengniu – all benefit from consolidation, innovation, or adult nutrition upside. A2M's supply risk creates an entry point for investors willing to stomach near-term volatility.
• Underweight on Nestle – the Wyeth brand portfolio is expected to underperform, offsetting the broader recovery in its infant nutrition business.
• The market is not fully pricing in the adult nutrition opportunity for Danone and Yili; valuation discounts may narrow as this segment ramps.

Appendix Data Summary (Key Expert Estimates)